Major depressive disorder (MDD) is a leading cause of disability worldwide and unfortunately no treatment without side effects is available. Previous reports have found unbalanced glutamate-glutamine cycle in the medial prefrontal cortex of mice with depression, which led to the interest in glutamine synthetase as a potential therapeutic target for treating MDD, since this enzyme is a regulator of this cycle.
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire Intra-Cellular Therapies Inc. for $132 per share, which equates to an equity value of about $14.6 billion.
Medtronic plc secured CE mark approval under the EU Medical Device Regulation for its Brainsense adaptive deep brain stimulation system. The technology represents a major advancement in the treatment of Parkinson’s disease as it provides real-time, self-adjusting brain stimulation based on the patient’s brain activity, offering a more personalized therapy.
In the first patenting to emerge from Carlsbad, Calif.-based Biologic Input Output Systems Inc., its chief development officer, Timothy Miller, collaborated with academics on the development of implantable neural interfaces for placement in the peripheral nervous system.
Ono Pharmaceutical Co Ltd., Vanderbilt University and Wuxi Apptec Co. Ltd. have disclosed potassium channel subfamily K member 2 (TREK-1; KCNK2) and or member 10 (TREK-2; KCNK10) blockers reported to be useful for the treatment of depression, schizophrenia, anxiety disorders and bipolar disorder, among others.
An F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent details new cannabinoid CB2 receptor modulators reported to be useful for the treatment of neuropathic pain, asthma, osteoporosis, inflammation, psychosis, cancer, malaria, gastrointestinal disorders, allergy and immunological disorders, among others.
Prothena Biosciences Ltd. and Vanderbilt University have jointly discovered dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of Alzheimer’s disease, cancer, diabetes, cardiovascular disorders and Down syndrome.
Work at Beijing Normal University and affiliated organizations has led to the discovery and preclinical characterization of a novel tau-PET radiotracer for Alzheimer’s disease (AD).
Data from two out of three positive studies faced the U.S. FDA’s Anesthetic and Analgesic Drug Products Advisory Committee as members examined the package submitted by Seikagaku Corp., of Tokyo, for SI-6603 (condoliase), a chemonucleolytic drug for radicular leg pain associated with lumbar disc hernia.
Brainaurora Medical Technology Ltd. debuted on the Hong Kong stock exchange Jan. 8 with a HK$583.18 million (US$74.93 million) IPO, offering about 181.11 million shares at HK$3.22 per share.
RSS
